155 related articles for article (PubMed ID: 1434755)
1. Updating RU 486 development.
Baulieu EE
Law Med Health Care; 1992; 20(3):154-6. PubMed ID: 1434755
[TBL] [Abstract][Full Text] [Related]
2. RU 486 in France and England: corporate ethics and compulsory licensing.
Boland R
Law Med Health Care; 1992; 20(3):226-34. PubMed ID: 1434766
[TBL] [Abstract][Full Text] [Related]
3. Antiprogestin drugs: research and clinical use in Sweden.
Bygdeman M; Swahn ML
Law Med Health Care; 1992; 20(3):157-60. PubMed ID: 1434756
[TBL] [Abstract][Full Text] [Related]
4. Steroid antagonists and receptor-associated proteins.
Lebeau MC; Baulieu EE
Hum Reprod; 1994 Mar; 9(3):437-44. PubMed ID: 8006131
[TBL] [Abstract][Full Text] [Related]
5. Mifepristone-misoprostol medical abortion: home administration of misoprostol in Guadeloupe.
Guengant JP; Bangou J; Elul B; Ellertson C
Contraception; 1999 Sep; 60(3):167-72. PubMed ID: 10640161
[TBL] [Abstract][Full Text] [Related]
6. Mifepristone (RU 486) in the United States. What does the future hold?
Rosenfield A
N Engl J Med; 1993 May; 328(21):1560-1. PubMed ID: 8479494
[TBL] [Abstract][Full Text] [Related]
7. Antiprogestin drugs: ethical, legal and medical issues.
Cook RJ; Grimes DA
Law Med Health Care; 1992; 20(3):149-53. PubMed ID: 1434754
[TBL] [Abstract][Full Text] [Related]
8. RU 486 approved in Britain; U.S. research still limited.
Contracept Technol Update; 1991 Sep; 12(9):144-7. PubMed ID: 12317312
[TBL] [Abstract][Full Text] [Related]
9. Low-dose mifepristone 200 mg and vaginal misoprostol for abortion.
Schaff EA; Eisinger SH; Stadalius LS; Franks P; Gore BZ; Poppema S
Contraception; 1999 Jan; 59(1):1-6. PubMed ID: 10342079
[TBL] [Abstract][Full Text] [Related]
10. Boycott threat forces French company to abandon RU486.
Dorozynski A
BMJ; 1997 Apr; 314(7088):1150. PubMed ID: 9146386
[TBL] [Abstract][Full Text] [Related]
11. Roussel-Uclaf to transfer RU 486 rights.
Reprod Freedom News; 1997 Apr; 6(7):8. PubMed ID: 12292550
[TBL] [Abstract][Full Text] [Related]
12. Mifepristone (RU486) alone or in combination with a prostaglandin analogue for termination of early pregnancy: a review.
Avrech OM; Golan A; Weinraub Z; Bukovsky I; Caspi E
Fertil Steril; 1991 Sep; 56(3):385-93. PubMed ID: 1894013
[TBL] [Abstract][Full Text] [Related]
13. RU-486: legal and policy issues confronting the Food and Drug Administration.
Muhl C
J Leg Med; 1993 Jun; 14(2):319-47. PubMed ID: 8340714
[TBL] [Abstract][Full Text] [Related]
14. Fertility control in women: results with RU 486 by the end of 1985.
Baulieu E
J Steroid Biochem; 1986 Nov; 25(5B):847-51. PubMed ID: 3807366
[TBL] [Abstract][Full Text] [Related]
15. Mifepristone (RU 486) for induced abortion.
Grimes DA
Womens Health Issues; 1993; 3(3):171-5. PubMed ID: 8274873
[TBL] [Abstract][Full Text] [Related]
16. Low-dose mifepristone followed by vaginal misoprostol at 48 hours for abortion up to 63 days.
Schaff EA; Fielding SL; Eisinger SH; Stadalius LS; Fuller L
Contraception; 2000 Jan; 61(1):41-6. PubMed ID: 10745068
[TBL] [Abstract][Full Text] [Related]
17. A novel approach to human fertility control: contragestion by the anti-progesterone RU 486.
Baulieu EE
Eur J Obstet Gynecol Reprod Biol; 1988 Jun; 28(2):125-9. PubMed ID: 3402651
[TBL] [Abstract][Full Text] [Related]
18. Analysis of 369 abortions conducted by mifepristone (RU486) associated with sulprostone in a French family planning center.
Thonneau P; Fougeyrollas B; Spira A
Fertil Steril; 1994 Apr; 61(4):627-31. PubMed ID: 7512053
[TBL] [Abstract][Full Text] [Related]
19. Introduction of abortion technologies: a quality of care management approach.
Greenslade FC; Winkler J; Leonard AH
Law Med Health Care; 1992; 20(3):161-8. PubMed ID: 1434757
[TBL] [Abstract][Full Text] [Related]
20. RU 486: an overview of mifepristone and its potential applications.
Contracept Rep; 1993 May; 4(2):7-9. PubMed ID: 12286473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
